Sirolimus in kidney transplantation indications and practical guidelines: de novo sirolimus-based therapy without calcineurin inhibitors.
about
Do wound complications or lymphoceles occur more often in solid organ transplant recipients on mTOR inhibitors? A systematic review of randomized controlled trialsReviewing 15 years of experience with sirolimusFirst-in-human study of the safety and efficacy of TOL101 induction to prevent kidney transplant rejectionSystemic meta-analysis assessing the short term applicability of early conversion to mammalian target of rapamycin inhibitors in kidney transplant.Rapamycin protects mice from staphylococcal enterotoxin B-induced toxic shock and blocks cytokine release in vitro and in vivo.Brucella Dysregulates Monocytes and Inhibits Macrophage Polarization through LC3-Dependent Autophagy.Sirolimus conversion efficacy for graft function improvement and histopathology in renal recipients with mild to moderate renal insufficiency.Immunosuppression in kidney transplantation.Intranasal rapamycin rescues mice from staphylococcal enterotoxin B-induced shock.Prospects for mTOR inhibitor use in patients with polycystic kidney disease and hamartomatous diseases.Clinical application of mTORi based immunosuppression for renal transplantation in India.Therapeutic down-modulators of staphylococcal superantigen-induced inflammation and toxic shock.Is Early Conversion to mTOR Inhibitors Represent a Suitable Choice in Renal Transplant Recipients? A Systemic Review of Medium-term OutcomesRapamycin unbalances the polarization of human macrophages to M1.Conversion to mammalian target of rapamycin inhibitors increases risk of de novo donor-specific antibodies.Proteinuria and sirolimus after renal transplantation: a retrospective analysis from a large German multicenter database.Randomized phase 2b trial of tofacitinib (CP-690,550) in de novo kidney transplant patients: efficacy, renal function and safety at 1 year.
P2860
Q26823281-B0AA765E-1EE7-4A29-B74A-40A6C4F50F99Q28080955-E1878C01-8F5A-4D50-9324-2F1045215C18Q30389408-5DD3B701-9222-45B8-A36D-400B1B7A283AQ33617408-B355F591-E8D3-4EF1-890E-C8EF0EAE3561Q33676236-05B074D3-5EDE-46BB-9BD0-E52796BCC347Q33785846-6511AE33-80ED-4A78-A805-BB188CB475E6Q34029931-B86FE209-B92E-487D-9672-E94153FD5B52Q35714310-5668B19C-7BF8-4995-896E-04F109DC9726Q36329660-A25827C2-B0B4-43A2-9B3E-8D8F2731077DQ37760379-830DFB8F-5C79-42F0-A6BB-EC6EC606610BQ37929851-F65E09BE-8944-4AE7-BEEC-4053AC9C2620Q37954312-21BCC8B3-9198-4642-9680-C5C515271B5FQ41313340-A79068D4-44A5-466A-B291-6D28F1235362Q45057583-A9EF7B30-EAE0-46DF-AC29-F09314D3C8FAQ51744862-3AF3603B-63E3-4F5A-9EC3-2E8B374E1B3AQ54392480-1F90934C-ECD6-427B-8DEC-375F29810D35Q54505605-9B49622E-C8CD-48ED-BBC0-7CD0AD522AA0
P2860
Sirolimus in kidney transplantation indications and practical guidelines: de novo sirolimus-based therapy without calcineurin inhibitors.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on April 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Sirolimus in kidney transplant ...... ithout calcineurin inhibitors.
@en
Sirolimus in kidney transplant ...... ithout calcineurin inhibitors.
@nl
type
label
Sirolimus in kidney transplant ...... ithout calcineurin inhibitors.
@en
Sirolimus in kidney transplant ...... ithout calcineurin inhibitors.
@nl
prefLabel
Sirolimus in kidney transplant ...... ithout calcineurin inhibitors.
@en
Sirolimus in kidney transplant ...... ithout calcineurin inhibitors.
@nl
P1433
P1476
Sirolimus in kidney transplant ...... ithout calcineurin inhibitors.
@en
P2093
Stuart M Flechner
P356
10.1097/TP.0B013E3181A059A1
P433
P577
2009-04-01T00:00:00Z